Literature DB >> 7730146

Preferential production of interleukin-1 beta over interleukin-1 receptor antagonist contributes to proliferation and suppression of apoptosis in leukemic cells.

Y Furukawa1, J Kikuchi, Y Terui, S Kitagawa, M Ohta, Y Miura, M Saito.   

Abstract

Normal human monocytes were isolated in a nascent state by centrifugal elutriation and used for the study of interleukin-1 (IL-1) and interleukin-1 receptor antagonist (IL-1ra) expression. Neither IL-1 beta nor IL-1ra mRNA was present in monocytes just after the isolation, but they were induced simultaneously in response to various stimulants. In contrast, only IL-1 beta mRNA was expressed in monocytic leukemia cell line JOSK-1, while little or no IL-1ra mRNA was detected even after stimulation. Dominant expression of IL-1 beta over IL-1ra was also observed in fresh leukemia cells including monocytic leukemias, i.e., IL-1 beta mRNA was constitutively expressed in 26 out of 36 cases (72.2%), whereas IL-1ra mRNA was present only in 8 cases (22.2%). The signal intensity of IL-1 beta mRNA was stronger than that of IL-1ra even in IL-1ra-positive cases. Apoptotic cell death of monocytes was significantly inhibited by IL-1 beta, and it was enhanced by IL-1ra. In fresh leukemia cells, 3H-thymidine uptake was generally higher in IL-1-producing cases than in IL-1ra-producing cases, and was increased by the addition of IL-1 beta in all cases tested. Cell proliferation was inhibited by either IL-1ra or anti-IL-1 beta antibody in IL-1-producing cases, while it was enhanced by anti-IL-1ra antibody in IL-1ra-producing cases. These results suggest that the balance between IL-1 and IL-1ra is necessary for homeostasis of the mononuclear phagocytosis system. The imbalance between these two counter-acting cytokines might contribute to the altered growth and accumulation of leukemic cells.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7730146      PMCID: PMC5920749          DOI: 10.1111/j.1349-7006.1995.tb03041.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  42 in total

1.  Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor.

Authors:  C H Hannum; C J Wilcox; W P Arend; F G Joslin; D J Dripps; P L Heimdal; L G Armes; A Sommer; S P Eisenberg; R C Thompson
Journal:  Nature       Date:  1990-01-25       Impact factor: 49.962

2.  Production of interleukin-1-receptor antagonist during experimental endotoxaemia.

Authors:  E V Granowitz; A A Santos; D D Poutsiaka; J G Cannon; D W Wilmore; S M Wolff; C A Dinarello
Journal:  Lancet       Date:  1991-12-07       Impact factor: 79.321

3.  Demonstration of interleukin-1 beta transcripts in acute myeloblastic leukemic cells by in situ hybridization.

Authors:  M Nakamura; Y Kanakura; Y Furukawa; T J Ernst; J D Griffin
Journal:  Leukemia       Date:  1990-07       Impact factor: 11.528

4.  Suppression of chronic myelogenous leukemia colony growth by interleukin-1 (IL-1) receptor antagonist and soluble IL-1 receptors: a novel application for inhibitors of IL-1 activity.

Authors:  Z Estrov; R Kurzrock; M Wetzler; H Kantarjian; M Blake; D Harris; J U Gutterman; M Talpaz
Journal:  Blood       Date:  1991-09-15       Impact factor: 22.113

5.  Purification, cloning, expression and biological characterization of an interleukin-1 receptor antagonist protein.

Authors:  D B Carter; M R Deibel; C J Dunn; C S Tomich; A L Laborde; J L Slightom; A E Berger; M J Bienkowski; F F Sun; R N McEwan
Journal:  Nature       Date:  1990-04-12       Impact factor: 49.962

Review 6.  Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis.

Authors:  W P Arend; J M Dayer
Journal:  Arthritis Rheum       Date:  1990-03

7.  Human IL-1 receptor antagonist promoter. Cell type-specific activity and identification of regulatory regions.

Authors:  M F Smith; D Eidlen; M T Brewer; S P Eisenberg; W P Arend; A Gutierrez-Hartmann
Journal:  J Immunol       Date:  1992-09-15       Impact factor: 5.422

8.  Transgenic mice expressing a hemopoietic growth factor gene (GM-CSF) develop accumulations of macrophages, blindness, and a fatal syndrome of tissue damage.

Authors:  R A Lang; D Metcalf; R A Cuthbertson; I Lyons; E Stanley; A Kelso; G Kannourakis; D J Williamson; G K Klintworth; T J Gonda
Journal:  Cell       Date:  1987-11-20       Impact factor: 41.582

9.  Rapid priming of human monocytes by human hematopoietic growth factors: granulocyte-macrophage colony-stimulating factor (CSF), macrophage-CSF, and interleukin-3 selectively enhance superoxide release triggered by receptor-mediated agonists.

Authors:  A Yuo; S Kitagawa; K Motoyoshi; E Azuma; M Saito; F Takaku
Journal:  Blood       Date:  1992-03-15       Impact factor: 22.113

10.  Production of IL-1 receptor antagonist by human in vitro-derived macrophages. Effects of lipopolysaccharide and granulocyte-macrophage colony-stimulating factor.

Authors:  R W Janson; K R Hance; W P Arend
Journal:  J Immunol       Date:  1991-12-15       Impact factor: 5.422

View more
  3 in total

1.  IL-1ra and IL-1 production in human oral mucosal epithelial cells in culture: differential modulation by TGF-beta1 and IL-4.

Authors:  S Perrier; B Kherratia; C Deschaumes; S Ughetto; J-L Kemeny; M Baudet-Pommel; B Sauvezie
Journal:  Clin Exp Immunol       Date:  2002-01       Impact factor: 4.330

2.  Overexpression of IL-1ra gene up-regulates interleukin-1beta converting enzyme (ICE) gene expression: possible mechanism underlying IL-1beta-resistance of cancer cells.

Authors:  M Sumitomo; M Tachibana; M Murai; M Hayakawa; H Nakamura; A Takayanagi; N Shimizu
Journal:  Br J Cancer       Date:  1999-09       Impact factor: 7.640

3.  Analysis of the expression and potential molecular mechanism of interleukin-1 receptor antagonist (IL1RN) in papillary thyroid cancer via bioinformatics methods.

Authors:  Zhenyu Xie; Xin Li; Yuzhen He; Song Wu; Shiyue Wang; Jianjian Sun; Yuchen He; Yu Lun; Shijie Xin; Jian Zhang
Journal:  BMC Cancer       Date:  2020-11-25       Impact factor: 4.430

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.